Ryoo B.-Y.Merle P.Kulkarni A.S.ANN-LII CHENGBouattour M.Lim H.Y.Breder V.Edeline J.Chao Y.Ogasawara S.Yau T.Garrido M.Chan S.L.Daniele B.Norquist J.M.Chen E.Siegel A.B.Zhu A.X.Finn R.S.Kudo M.2021-08-312021-08-3120210008-543Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85096702993&doi=10.1002%2fcncr.33317&partnerID=40&md5=2afb97255cd8773db5854fe3a946987ehttps://scholars.lib.ntu.edu.tw/handle/123456789/580013Background: Health-related quality of life (HRQoL) is an important outcome measure and prognostic indicator in hepatocellular carcinoma (HCC). KEYNOTE-240 (NCT02702401) assessed the efficacy and safety of pembrolizumab plus best supportive care (BSC) vershepatocellular carcinoma; immunotherapy; patient-reported outcome measures; pembrolizumab; quality of life[SDGs]SDG3pembrolizumab; placebo; monoclonal antibody; pembrolizumab; abdominal swelling; adult; advanced cancer; Article; cancer palliative therapy; controlled study; deterioration; drug efficacy; drug safety; European Organization for Research and Treatment of Cajournal article10.1002/cncr.33317332318732-s2.0-85096702993